Prana Biotech (ASX:PBT, NASDAQ:PRAN) announced today that its candidate PBT2 therapy for Alzheimer's disease has come through a phase I single-dose escalation trial in the Netherlands, with a superior pharmacokinetic profile to its predecessor, clioquinol. More...
